1. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. (20th October 2022) Authors: Lorusso, Domenica; Makker, Vicky; Herraez, Antonio Casado; Monk, Bradley J; Mackay, Helen; Santin, Alessandro D; Miller, David S; Moore, Richard; Baron-Hay, Sally; Ray-Coquard, Isabelle; Shapira-Frommer, Ronnie; Ushijima, Kimio; Yonemori, Kan; Kim, Yong Man; Guerra Alia, Eva M; Sanli, Ulus A; Hua... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: study 309/keynote-775. (4th December 2022) Authors: Makker, Vicky; Colombo, Nicoletta; Herráez, Antonio Casado; Monk, Bradley; Mackay, Helen; Santin, Alessandro; Miller, David; Moore, Richard; Ray-Coquard, Isabelle; Shapira-Frommer, Ronnie; Ushijima, Kimio; Yonemori, Kan; Kim, Yong Man; Alia, Eva Guerra; Sanli, Ulus; Xie, Ran; Zale, Melissa; Mcken... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗